This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
February 02, 2017
Targovax announces encouraging top line two-year survival data from TG01 clinical trial in resected pancreatic cancer patients
February 02, 2017
Strongbridge Biopharma plc to Participate in the Canaccord Genuity Rare Disease and BioPharma One-on-One Day
January 31, 2017
Neurosurgeons from Germany and U.S.A. report on their clinical experience of using Nexstim NBS system
January 31, 2017
Radiotherapy, immunotherapy and DNA repair inhibitors: a winning combination towards the oncology of the future
January 31, 2017
GenSight Biologics receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa
January 27, 2017
GenSight Biologics reports its cash position as of December 31, 2016
January 24, 2017
Onxeo Completes Enrollment in Phase III Study of Livatag® for the Treatment of Hepatocellular Carcinoma
January 19, 2017
PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases
January 19, 2017
Clinical progress, cash position and revenue for Q4 2016
January 11, 2017
Nexstim Plc announces signing of an Independent Selling Representative Agreements in U.S.